🔗 Share this article

While the United States continues making unprecedented adjustments to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccines in the pandemic and has focused upon possible deaths following COVID-19 immunization in her short position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities had intended to announce radical revisions to the pediatric vaccination calendar in December, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with many the world with no evidence for improved outcomes. The planned update has been pushed back until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the center this year.

Consolidating Power at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for ending specific childhood vaccine recommendations in the US so as to align more like Denmark, a country with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

The appointee has no obvious experience in medication creation, regulation or administrative roles, which has been customary for past heads of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Past directors of the center would “understand regulatory frameworks and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who headed CBER have had.”

The drug center has an vast range of responsibilities at the FDA, she emphasized.

“Everybody just focuses on the new drug program, but the generic program approves thousands of generic medications. There is also a biosimilars division, OTC medication office and more, and each of these must be managed,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative aspect to the job, which oversees more than 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock added.

Response and Disputed Programs

When asked about questions about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on vaccines, a spokesperson said that the “questions are based on inaccurate premises”.

“Her experience is consistent with the duties of her role,” the representative stated, pointing to the period Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new priority voucher program, a contentious one-day therapy clearance system that reportedly worried her former heads. “By what process are these therapies being selected for this fast-track system? Who is making the choices?” Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, aside from shots.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, track record, some experts observe. She authored a research paper using unverified crowd-sourced reports to assess the frequency of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the new government included altering guidelines for recently developed shots and ending “unnecessary” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing young men from obtaining Covid vaccinations.

“She’s an complete true believer who starts off with her conclusions and reverse-engineers to accommodate the evidence in a extremely misleading, dishonest fashion,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|